For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ HGH Fragment 176-191
Illustration for HGH Fragment 176-191

THE PEPSRADAR ENCYCLOPEDIA

HGH Fragment 176-191

Fragment identity and fat-metabolism research

Research topics · Sources checked 2026-10-04

Read the studies ↓

HGH Fragment 176-191 · KEY FACTS

Content updated · how dates work

Saved peptides

Compare: AOD-9604 vs HGH Fragment 176-191

What is HGH Fragment 176-191?

HGH Fragment 176-191 is a label for a growth-hormone C-terminal fragment. The selected primary paper studied the related 177-191 fragment, so it is background evidence rather than confirmation of the exact 176-191 product.

Biological role or research focus

Fragment identity and fat-metabolism research.

The selected study used a related fragment, not confirmed 176-191. It does not establish clinical fat loss or equivalence to AOD-9604.

Role reference: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

Names you may encounter

GH fragment 176-191 · Human growth hormone fragment 176-191

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Growth-hormone C-terminal fragment label
Research focus
Fragment identity and fat-metabolism research
Featured evidence
Related fragment · Animal tissue study
Source check
October 4, 2026

Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

Quick answers

Is HGH Fragment 176-191 FDA approved?
No. No FDA-approved drug contains HGH Fragment 176-191. Source ↗
Is HGH Fragment 176-191 safe?
HGH Fragment 176-191 has no published human safety studies. Its evidence comes from lab studies of related growth-hormone fragments. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is HGH Fragment 176-191 banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.3 Growth hormone fragments). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Related compound / review
StudyTypePopulation / model
GH fragment 177-191 in rat adipose tissue (1993)Related fragment · Animal tissue studyRat adipose-tissue preparations.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Related fragment · Animal tissue study · 1993

GH fragment 177-191 in rat adipose tissue

What did this publication test, and what did it find?

Population / model
Rat adipose-tissue preparations.
Study design
Laboratory comparison of a synthetic GH 177-191 fragment using fat-synthesis and glycerol-release measurements.
Main finding
The fragment showed antilipogenic activity, but it did not significantly increase glycerol release as a lipolysis measure.
Limits & context
The selected study used a related fragment, not confirmed 176-191. It does not establish clinical fat loss or equivalence to AOD-9604.

Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming HGH Fragment 176-191 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 1 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. ↗
Drug design, development and therapy · 2022 · Journal Article
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

HGH Fragment 176-191 has no published human safety studies. Its evidence comes from lab studies of related growth-hormone fragments.

Human safety data: None

No human safety studies were found for this exact fragment. Human trials of the related AOD-9604 do not establish its safety, and products sold under this name may differ in identity.

Unassessed: no human safety data

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Antilipogenic action of GH sequence 177-191 in rat tissue (1993) ↗

Safety & what remains unknown

This tissue experiment does not define systemic or human safety for any of these fragments.

Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

Evidence boundaries

The selected study used a related fragment, not confirmed 176-191. It does not establish clinical fat loss or equivalence to AOD-9604.

Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.2.3 Growth hormone fragments
Named explicitly ("hGH 176-191"). source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

This page separates fragments 176-191 and 177-191 from modified AOD-9604. Sequence and terminal modifications are necessary to identify the actual material.

Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Biology & proposed mechanism

The experiment distinguished inhibition of fat synthesis from stimulation of fat breakdown. Those mechanisms should not be collapsed into a general weight-loss claim.

Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

Questions worth asking

  • Are 176-191, 177-191, and AOD-9604 automatically interchangeable?
  • What material, population, and route were actually studied?
  • The selected study used a related fragment, not confirmed 176-191. It does not establish clinical fat loss or equivalence to AOD-9604.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Are 176-191, 177-191, and AOD-9604 automatically interchangeable?

No. The exact sequence and modifications must be retained. This paper’s 177-191 result is labeled as related evidence.

Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. · 1993 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections